Insights

Marwood’s Mark Slomiany addresses the growing orphan drug affordability challenge to payors and emerging countermeasures to mitigate their impact. 

In-home HRAs have seen increased attention over the last year, both in their importance to MA plans, as well as potential regulatory concerns. Marwood’s Joseph Mercer examines policy considerations for deals like CVS Health and Signify Health, in light of Congressional and CMS views on in-home HRAs and potential risk adjustment reform, Medicare trust fund solvency fixes, and increased antitrust activity by FTC and DOJ.

Pharma hub services continue to expand with the rise of specialty drugs. Herein, Mark Slomiany addresses their features, transactional trends and regulatory considerations in the patient assistance ecosystem.

The burgeoning telepsychiatry space faces rapidly evolving regulatory and competitive dynamics.  Marwood Group’s Mark Slomiany examines the market landscape and policy considerations in this behavioral health subsector as the public health emergency draws to an end.

Independent community pharmacies, once written off, are benefiting from the tailwinds of a post-big box store era. Herein, Marwood’s Mark Slomiany elaborates on how the current landscape benefits nimble independent community pharmacies that not only achieve cost control but diversify their services.

The recent spike in inflation has yet to fully percolate through the healthcare value chain. Marwood’s Mark Slomiany provides perspective on payor and provider measures and countermeasures likely to accelerate trends reshaping the industry.

In part two of Marwood’s CDMO outlook, Mark Slomiany and Tim Read explore the role CDMOs have played in supporting the pharmaceutical sector, as well as core areas inflecting growth, the evolving M&A landscape, and regulatory considerations.